PROCEPT BioRobotics Corporation Common Stock PRCT
i
Market dataready · fetched 2026-11-07T07:50:33.669Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-07T00:54:03.81700395Z
FundamentalsSEC EDGAR · ready · as of 2026-09-30 · fetched 2026-11-07T07:50:33.233553+00:00
PROCEPT BioRobotics Corporation Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 24.03 | 86.2% | 18.9% | 17.80 | 103.4% | 16.2% |
| 25Δ | 23.56 | 91.7% | 17.3% | 18.34 | 110.0% | 14.9% |
| 30Δ | 23.09 | 97.2% | 15.7% | 18.88 | 116.6% | 13.7% |
| 35Δ | 22.62 | 102.6% | 14.2% | 19.42 | 123.2% | 12.4% |
| 40Δ | 22.11 | 102.4% | 12.5% | 19.96 | 129.8% | 11.1% |
| 45Δ | 21.58 | 100.3% | 10.8% | 20.44 | 123.4% | 9.7% |
| 50Δ | 21.06 | 98.2% | 9.1% | 20.91 | 115.7% | 8.2% |
| 55Δ | 20.53 | 96.1% | 7.4% | 21.38 | 108.1% | 6.7% |
| 60Δ | 20.01 | 93.9% | 5.8% | 21.86 | 100.5% | 5.3% |
| 65Δ | 22.33 | 92.9% | 3.8% | |||
| 70Δ | 22.86 | 88.6% | 2.9% | |||
| 75Δ | 23.43 | 86.1% | 2.3% | |||
| 80Δ | 23.99 | 83.6% | 1.7% | |||
20Δ
- Pseudo strike
- 24.03
- IV
- 86.2%
- B/E move
- 18.9%
- Pseudo strike
- 17.80
- IV
- 103.4%
- B/E move
- 16.2%
25Δ
- Pseudo strike
- 23.56
- IV
- 91.7%
- B/E move
- 17.3%
- Pseudo strike
- 18.34
- IV
- 110.0%
- B/E move
- 14.9%
30Δ
- Pseudo strike
- 23.09
- IV
- 97.2%
- B/E move
- 15.7%
- Pseudo strike
- 18.88
- IV
- 116.6%
- B/E move
- 13.7%
35Δ
- Pseudo strike
- 22.62
- IV
- 102.6%
- B/E move
- 14.2%
- Pseudo strike
- 19.42
- IV
- 123.2%
- B/E move
- 12.4%
40Δ
- Pseudo strike
- 22.11
- IV
- 102.4%
- B/E move
- 12.5%
- Pseudo strike
- 19.96
- IV
- 129.8%
- B/E move
- 11.1%
45Δ
- Pseudo strike
- 21.58
- IV
- 100.3%
- B/E move
- 10.8%
- Pseudo strike
- 20.44
- IV
- 123.4%
- B/E move
- 9.7%
50Δ
- Pseudo strike
- 21.06
- IV
- 98.2%
- B/E move
- 9.1%
- Pseudo strike
- 20.91
- IV
- 115.7%
- B/E move
- 8.2%
55Δ
- Pseudo strike
- 20.53
- IV
- 96.1%
- B/E move
- 7.4%
- Pseudo strike
- 21.38
- IV
- 108.1%
- B/E move
- 6.7%
60Δ
- Pseudo strike
- 20.01
- IV
- 93.9%
- B/E move
- 5.8%
- Pseudo strike
- 21.86
- IV
- 100.5%
- B/E move
- 5.3%
65Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 22.33
- IV
- 92.9%
- B/E move
- 3.8%
70Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 22.86
- IV
- 88.6%
- B/E move
- 2.9%
75Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 23.43
- IV
- 86.1%
- B/E move
- 2.3%
80Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 23.99
- IV
- 83.6%
- B/E move
- 1.7%
Options history
Table
| Date | IV (%) |
|---|---|
| 71.09% | |
| 66.97% | |
| 71.21% | |
| 60.55% | |
| 62.02% | |
| 63.93% | |
| 62.89% | |
| 66.86% | |
| 63.39% | |
| 61.65% | |
| 61.45% | |
| 61.78% | |
| 65.57% | |
| 64.05% | |
| 63.21% | |
| 75.09% | |
| 66.78% | |
| 65.50% | |
| 67.36% | |
| 100.34% | |
| 68.78% | |
| 76.40% | |
| 71.77% | |
| 66.18% | |
| 67.65% | |
| 65.48% | |
| 64.50% | |
| 72.99% | |
| 88.03% | |
| 74.38% | |
| 76.12% | |
| 81.51% | |
| 83.16% | |
| 88.81% | |
| 89.81% | |
| 80.78% | |
| 73.56% | |
| 76.32% | |
| 75.31% | |
| 77.48% | |
| 74.60% | |
| 70.34% | |
| 70.36% | |
| 71.86% | |
| 69.30% | |
| 81.25% |
Medical Devices
PROF
Profound Medical Corp. The company is headquartered in Mississauga, Canada.
More →QDEL
Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for infectious disease, cardiology, thyroid, general and women's health, eye health,…
More →QSI
Quantum-Si incorporated operates the first next-generation protein sequencing platform for the healthcare industries.
More →QTRX
Quanterix Corporation, a life sciences company, develops and markets digital immunoassay platforms that advance precision health for life sciences research and diagnostics in…
More →RCEL
Description unavailable
More →RXST
Rxsight Inc. is a cutting-edge healthcare technology company dedicated to transforming vision correction through advanced diagnostic and surgical solutions in refractive eye…
More →